Anti-Xa activity in apixaban overdose: a case report

被引:14
作者
Barton, James [1 ]
Wong, Anselm [1 ,2 ]
Graudins, Andis [1 ,2 ]
机构
[1] Monash Hlth, Monash Clin Toxicol, Program Emergency Med, Clayton, Vic, Australia
[2] Monash Univ, Fac Med Nursing & Hlth Sci, Monash Hlth, Sch Clin Sci, Clayton, Vic 3800, Australia
关键词
Factor Xa inhibitors; oral anticoagulants; toxicokinetics; RIVAROXABAN; INHIBITOR; PHARMACOKINETICS; ASSAYS; PHARMACODYNAMICS; PROTHROMBIN; REVERSAL; SAFETY; GUIDE;
D O I
10.1080/15563650.2016.1204453
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Introduction: Apixaban is a novel oral anticoagulation agent that exerts its effect through direct factor Xa inhibition. We present a case of multi-drug overdose including apixaban with associated apixaban concentrations.Case: A 53 year-old man presented to our metropolitan hospital following a deliberate self-poisoning with 200mg apixaban, 35mg ramipril, 105mg bisoprolol, 280mg atorvastatin, 6mg colchicine, 37.4mg magnesium, 4x500mg paracetamol/9.5mg codeine/5mg phenylephrine and alcohol. He developed hypotension that was treated with noradrenaline. His initial and peak apixaban concentration was 1022.6ng/ml and was associated with only minor bleeding from his femoral central line insertion site, which improved with local compression. Vitamin K 10mg (at 9h post-ingestion) and Prothrombinex-VF 2000 units (at 13h post-ingestion) were also administered without any observed effect on coagulation studies. Apixaban elimination appeared to display first-order kinetics with an elimination half-life of 7.4h. His plasma apixaban concentration was within the therapeutic dose range 10h post-ingestion and he recovered uneventfully.Conclusion: A case of apixaban overdose with associated apixaban concentrations is presented. There was rapid resolution of anticoagulation with no demonstrable benefit of currently available clotting factor replacement.
引用
收藏
页码:871 / 873
页数:3
相关论文
共 15 条
  • [1] Who, when, and how to reverse non-vitamin K oral anticoagulants
    Aronis, Konstantinos N.
    Hylek, Elaine M.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2016, 41 (02) : 253 - 272
  • [2] Chromogenic laboratory assays to measure the factor Xa-inhibiting properties of apixaban-an oral, direct and selective factor Xa inhibitor
    Becker, Richard C.
    Yang, Hongqiu
    Barrett, Yuchen
    Mohan, Puneet
    Wang, Jessie
    Wallentin, Lars
    Alexander, John H.
    [J]. JOURNAL OF THROMBOSIS AND THROMBOLYSIS, 2011, 32 (02) : 183 - 187
  • [3] Bristol Myers Squibb Australia, 2016, PRODU INF DL R AP
  • [4] Comparison of the effects of apixaban and rivaroxaban on prothrombin and activated partial thromboplastin times using various reagents
    Dale, B. J.
    Ginsberg, J. S.
    Johnston, M.
    Hirsh, J.
    Weitz, J. I.
    Eikelboom, J. W.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2014, 12 (11) : 1810 - 1815
  • [5] Safety of prothrombin complex concentrates for rapid anticoagulation reversal of vitamin K antagonists A meta-analysis
    Dentali, Francesco
    Marchesi, Chiara
    Pierfranceschi, Matteo Giorgi
    Crowther, Mark
    Garcia, David
    Hylek, Elaine
    Witt, Daniel M.
    Clark, Nathan P.
    Squizzato, Alessandro
    Imberti, Davide
    Ageno, Walter
    [J]. THROMBOSIS AND HAEMOSTASIS, 2011, 106 (03) : 429 - 438
  • [6] Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide
    Douxfils, Jonathan
    Chatelain, Christian
    Chatelain, Bernard
    Dogne, Jean-Michel
    Muller, Francois
    [J]. THROMBOSIS AND HAEMOSTASIS, 2013, 110 (02) : 283 - 294
  • [7] Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects
    Frost, Charles
    Wang, Jessie
    Nepal, Sunil
    Schuster, Alan
    Barrett, Yu Chen
    Mosqueda-Garcia, Rogelio
    Reeves, Richard A.
    LaCreta, Frank
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 75 (02) : 476 - 487
  • [8] Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
    Frost, Charles E.
    Byon, Wonkyung
    Song, Yan
    Wang, Jessie
    Schuster, Alan E.
    Boyd, Rebecca A.
    Zhang, Donglu
    Yu, Zhigang
    Dias, Clapton
    Shenker, Andrew
    LaCreta, Frank
    [J]. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (05) : 838 - 846
  • [9] Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays
    Gouin-Thibault, Isabelle
    Flaujac, Claire
    Delavenne, Xavier
    Quenet, Sara
    Horellou, Marie-Helene
    Laporte, Silvy
    Siguret, Virginie
    Lecompte, Thomas
    [J]. THROMBOSIS AND HAEMOSTASIS, 2014, 111 (02) : 240 - 248
  • [10] Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects
    Kubitza, Dagmar
    Becka, Michael
    Roth, Angelika
    Mueck, Wolfgang
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (10) : 2757 - 2765